← Back to Clinical Trials
Recruiting Phase 2 NCT04141020

NCT04141020 Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04141020
Status Recruiting
Phase Phase 2
Sponsor University of Miami
Condition Cerebral Aneurysm
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2021-10-27
Primary Completion 2026-11-01

Trial Parameters

Condition Cerebral Aneurysm
Sponsor University of Miami
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 80
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2021-10-27
Completion 2026-11-01
Interventions
Microsurgical clippingEndovascular treatmentSirolimus

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The objective of this study is to explore the effects of Sirolimus on the underlying molecular alterations of cerebral aneurysms.

Eligibility Criteria

Inclusion Criteria: 1. Undergoing one of the following procedures at Jackson Memorial Hospital: * Clipping of an unruptured cerebral artery aneurysm * Endovascular treatment of unruptured cerebral aneurysms (including those receiving coiling) 2. ≥ 18 years of age 3. Willing and able to give informed consent Exclusion Criteria: 1\) Subjects meeting any of the following criteria will be excluded: * Dissecting, traumatic, or mycotic brain aneurysm. * Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test. * Women who are breastfeeding. * Any clinically significant psychiatric or psychological disease, which would preclude the patient from completing the protocol. * Patients with known Human Immunodeficiency Virus (HIV) infection or other known immunodeficiency. * Patient with renal or liver failure * Interstitial pneumonitis * History of lymphoma * History of skin cancer * Hypersensitivity to sirolimus * Severe or unstable concomitant condition disease or chronic

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology